Delivery Order SPE2DB20D2104-SPE2DB24FMCEA

Award Date 9/23/24
Potential Completion Date 9/24/24
Potential Value $25K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of XIFAXAN 550 mg tablets to the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $24,356.37, was made to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, through a delivery order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical. This IDC, valued up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of...
This federal contract award is for the delivery of XIFAXAN 550 mg tablets to the Defense Logistics Agency (DLA). The Firm Fixed Price contract, valued at $5,766.59, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on January 18, 2023, with a completion date of January 19, 2023. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which...
This federal contract award is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $2,525.09 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of November 13, 2024. This delivery order is part of a broader Indefinite Delivery Contract (IDC) worth $999,999,999 that AmerisourceBergen holds with...
This contract award represents a delivery order for XIFAXAN 550 MG TABLET 60S placed with AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,211.93 firm-fixed-price contract was awarded by the Defense Logistics Agency (DLA), a defense agency responsible for providing supplies and services to the U.S. military. The contract has an ultimate completion date of February 7, 2025 and is not associated with a set-aside program. AmerisourceBergen...
This contract award is for the delivery of XIFAXAN 550MG 60S tablets, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $6,183.82, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a firm fixed-price pricing type and an ultimate completion date of January 2, 2025. AmerisourceBergen is the prime contractor and holds an Indefinite Delivery Contract (IDC)...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the supply of XIFAXAN 550 mg tablets to the Defense Logistics Agency (DLA). The contract is a Delivery Order with a Firm Fixed Price of $30,902.72 and an ultimate completion date of July 17, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This federal contract award is a delivery order worth $11,191.84 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a completion date of May 22, 2025. The contract is a firm fixed-price arrangement and does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,516.51 firm-fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of January 5, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,418.79, is for the delivery of XIFAXAN 550 MG tablets. The award does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,736.66 firm fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of February 26, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB24FMCEA
    Delivery Order

This federal contract award is for the delivery of XIFAXAN 550 mg tablets, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $24,557.16, is a Firm Fixed Price Delivery Order awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award does not have a set-aside designation, indicating open competition.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies for military personnel, veterans, and other federal beneficiaries.

Generated 2/27/25, 11:56 AM